News and Trends 26 Mar 2020 Novacyt Launches Two-Hour Coronavirus Test After FDA Approval The French clinical diagnostics specialist Novacyt has announced FDA authorization for its fast and easily transportable test for the coronavirus disease COVID-19. The company is also rolling out the kit this week via manufacturing and distribution partnerships across Europe. The test received an Emergency Use Authorization from the FDA, which means it can only be […] March 26, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Mar 2020 DBV Technologies’ Peanut Allergy Treatment Hits FDA Setback French biotech DBV Technologies’ bid for the US approval of a skin patch to treat nut allergies could be delayed as the FDA requested more information on the patch’s efficacy. Specifically, the FDA requested more information on patch-site adhesion – critical to the patch working effectively – as well as its long-term efficacy. According to […] March 25, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2020 Coronavirus Delays Sensorion’s Hearing Loss Phase II Trial The French company Sensorion has been forced to delay a phase II trial in people with hearing loss due to slow patient recruitment amid the current coronavirus disease (Covid-19) pandemic. The clinical trial is designed to test Sensorion’s lead candidate drug in people with sudden sensorineural hearing loss, a rare disorder where the patient can […] March 16, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2020 Immune Marker in Blood May Predict Kidney Transplant Rejection Risk French researchers have found that the levels of certain immune cells in the blood of kidney transplant recipients may predict their future risk for transplant rejection. At present, kidney transplantation is the best treatment for people with end-stage renal disease but introducing a ‘foreign’ organ into someone’s body comes with the risk of rejection by […] March 13, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2020 Phase III Fail for MedDay’s Multiple Sclerosis Treatment A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial received either a placebo or a high dose of pharmaceutical-grade Biotin, also known as vitamin B₇. The patients had various forms of the autoimmune condition […] March 11, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2020 Update: Carmat’s Artificial Heart Reaches Two Year Milestone Update (11/03/2020): In a record first, Carmat announced today that one patient in its artificial heart trial has had the device implanted for 2 years. “Passing a two-year period of individual functioning is very encouraging, and confirms the capacity of our device to provide long-term support, which is one of our two key objectives along […] March 11, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2020 French Startup Raises €6M to Develop Cheap Single-Cell Sequencing Kits Scipio bioscience has raised €6M in a Series A round to launch cost-effective single-cell RNA sequencing kits, which could have big potential in profiling cells for research and clinical diagnostics. The round was led by M Ventures, the corporate venture capital arm of Merck. Other investors in the round included Seventure Partners’ seed fund Quadrivum […] February 26, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Feb 2020 Novadiscovery Carries out Clinical Trials using AI and Simulations Novadiscovery, based in Lyon, France, is developing AI-based simulation technology to predict clinical trial outcomes and cut their running costs. Mission: To predict the outcomes of clinical trials in silico using a combination of artificial intelligence (AI) and computational models of the biology underlying the disease. Clinical trials cost the healthcare industry billions of euros […] February 14, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2020 Charcoal-Based Treatment Can Protect Gut Microbiome from Antibiotics Ingestible pellets containing a charcoal-like treatment — designed by the French company Da Volterra — can stop the microbiome from being disrupted in hospitalized patients treated with antibiotics. The treatment also showed the potential to reduce the risk of Clostridium difficile gut infections in a phase II trial. When patients are given antibiotics for infections, […] February 12, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2020 Valbiotis Teams up with Nestlé to Reduce Type 2 Diabetes Risk In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M […] February 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2020 Off-The-Shelf Lung Cancer Vaccine Clinical Trial Gets €20M Boost The French-Belgian company PDC*Line Pharma has raised a €20M Series B round to fund an ongoing phase I/II trial of its off-the-shelf therapeutic vaccine for lung cancer. The total €20M consists of €13.9M in equity investments and €6.1M in loans and subsidies from the Walloon Region of Belgium. PDC*Line’s current investors took part in the […] January 22, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2020 Biotech Investment Firm Jeito Capital Launches with €200M Fund The French investment firm Jeito Capital has launched this week with a €200M fund that will support up to 15 drug-development start-ups with a focus on European companies. Jeito Capital is the brainchild of Rafaèle Tordjman, whose background in medicine and research as well as investment in life sciences led her to setting up the […] January 16, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email